Asgeirsson B, Grände P O, Nordström C H
Department of Anaesthesia and Intensive Care, University Hospital of Lund, Sweden.
Intensive Care Med. 1994;20(4):260-7. doi: 10.1007/BF01708961.
To evaluate a new therapy of posttraumatic brain oedema, with the main concept that opening of the blood-brain barrier upsets the normal brain volume regulation, inducing oedema formation. This means that transcapillary fluid fluxes will be controlled by hydrostatic capillary and colloid osmotic pressures, rather than by crystalloid osmotic pressure. If so, brain oedema therapy should include reduction of hydrostatic capillary pressure and preservation of normal colloid osmotic pressure.
11 severely head injured comatose patients with brain swelling, raised intracranial pressure (ICP), and impaired cerebrovascular response to hyperventilation.
To reduce capillary hydrostatic pressure the patients were given hypotensive therapy (beta 1-antagonist, metoprolol and alpha 2-agonist, clonidine) and a potential precapillary vasoconstrictor (dihydroergotamine). The latter may also decrease cerebral blood volume through venous capacitance constriction. Colloid osmotic pressure was maintained by albumin infusions. The concept implies the need of a negative fluid balance with preserved normovolaemia.
ICP decreased significantly within a few hours of treatment with unaltered perfusion pressure in spite of lowered blood pressure. Of 11 patients 9 survived with good recovery/moderate disability, 2 died. This was compared to outcome in a historical control group with identical entry criteria, given conventional brain oedema therapy, where mortality/vegetativity/severe disability was 100%.
The results indicate that the therapy should focus on extracellular rather than intracellular oedema and that ischemia is not the main triggering mechanism behind oedema formation. We suggest that our therapy is superior to conventional therapy by preventing herniation during the healing period of the blood-brain barrier.
评估一种创伤后脑水肿的新疗法,其主要理念是血脑屏障的开放会扰乱正常的脑容量调节,从而诱发水肿形成。这意味着跨毛细血管的液体通量将由毛细血管静水压和胶体渗透压控制,而非晶体渗透压。若如此,脑水肿治疗应包括降低毛细血管静水压并维持正常胶体渗透压。
11例重度颅脑损伤昏迷患者,伴有脑肿胀、颅内压(ICP)升高以及脑血管对过度通气反应受损。
为降低毛细血管静水压,给予患者降压治疗(β1受体拮抗剂美托洛尔和α2受体激动剂可乐定)以及一种潜在的毛细血管前血管收缩剂(双氢麦角胺)。后者还可能通过静脉容量血管收缩来减少脑血容量。通过输注白蛋白维持胶体渗透压。该理念意味着需要保持负液体平衡并维持正常血容量。
尽管血压降低,但在治疗后数小时内ICP显著下降,灌注压未改变。11例患者中9例存活,恢复良好/有中度残疾,2例死亡。这与一个具有相同入选标准、接受传统脑水肿治疗的历史对照组的结果进行比较,该对照组的死亡率/植物状态/严重残疾率为100%。
结果表明该疗法应关注细胞外而非细胞内水肿,且缺血并非水肿形成的主要触发机制。我们认为我们的疗法在血脑屏障愈合期预防脑疝方面优于传统疗法。